Clinical Trials Logo

CCND2 Gene Amplification clinical trials

View clinical trials related to CCND2 Gene Amplification.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02785939 Completed - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.